Revenue segments as reported by the company.

U.S. Healthcare Solutions

International Healthcare Solutions

Pharmaceutical Distribution Services

Other

Intersegment eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, and administrative

Depreciation and amortization

Employee severance, litigation, and other

Goodwill impairment

Impairment of assets

Acquisition, integration, and restructuring expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cencora Inc

CoreSite Realty Corporation owns, develops, and operates data centers in certain data center markets in the United States, including Los Angeles, the San Francisco Bay and Northern Virginia areas, Chicago, and New York City. Its customer base consists of enterprise customers, communications service providers, media and content companies, government agencies, and educational institutions.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Cencora Inc (COR) excels in Q3, eyes growth through strategic partnerships

Cencora's Q3 performance reflects strong growth and strategic positioning in the healthcare industry. Leveraging its leadership in specialty services, the company aims to capitalize on opportunities through partnerships and customer-centric strategies while addressing challenges in managing key financial factors.

Cencora Inc posts robust fiscal 2024 results, eyes strategic expansion

Cencora Inc's Q4 2024 earnings call highlighted strong financial performance, strategic acquisitions, and concerns about future challenges. The company's focus on expanding into new specialties and managing potential headwinds demonstrates a proactive approach to growth and risk management.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments. The U.S. Healthcare Solutions segment is involved in the offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers. The International Healthcare Solutions segment includes businesses that focus on international pharmaceutical wholesale and related service operations, and global commercialization services. The company was founded by Emil P. Martini in 1947 and is headquartered in Conshohocken, PA.

Cencora (COR) came out with quarterly earnings of $3.34 per share, beating the Zacks Consensus Estimate of $3.18 per share. This compares to earnings of $2.92 per share a year ago.

Cencora (COR) Surpasses Q3 Earnings and Revenue Estimates

Cencora raised its annual profit forecast again on Wednesday, driven by strong demand for high-priced specialty medicines that treat complex diseases such as cancer.

Cencora raises annual profit forecast on strong demand for specialty medicines

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 third quarter ended June 30, 2024, revenue increased 10.9 percent year-over-year to $74.2 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.42 for the third quarter of fiscal 2024 compared to $2.35 in the prior year third quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described bel.

Cencora Reports Fiscal 2024 Third Quarter Results

GE HealthCare Technologies Inc

Glaukos

DENTSPLY SIRONA

Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, XRAY, GEHC and GKOS are placed ahead of their earnings release.

Will These 4 MedTech Stocks Beat Forecasts This Earnings Season?

Evaluate the expected performance of Cencora (COR) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Countdown to Cencora (COR) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

Cencora's (COR) third-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.

Cencora (COR) to Report Q3 Earnings: Is a Beat in Store?

Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Cencora (COR) is Poised to Beat Earnings Estimates Again

Apple

Accenture Plc

Automatic Data Processing

Arthur J. Gallagher & Co.

A. O. Smith

Air Products and Chemicals

Amphenol

Atmos Energy

American States Water

Becton, Dickinson and Co.

Brown & Brown

Chubb

Colgate-Palmolive

Comcast

Canadian National Railway Company

Costco

Cisco Systems

Cintas Corp

California Water Service Group

Fastenal

Franklin Electric

General Dynamics

Graco

This article updates one I wrote in August 2022, which was based on a template article by David Van Knapp published in June 2020. I use an adapted quality scoring system to assess the quality of dividend growth stocks. The system employs six quality indicators from independent sources and assigns 0-5 points to each quality indicator, for a maximum of 30 points.

The Highest Quality Dividend Growth Stocks In 2024

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2024 on Wednesday, July 31, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on July 31, 2024. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executive Vice President &.

Cencora Announces Date and Time for Third Quarter Fiscal 2024 Earnings Release

Lithia Motors

Investors always praise compounder-type stocks, which are known for their proven ability to exponentially grow wealth over time. These companies usually achieve a high return on capital invested (ROCE) and return on equity (ROE).

3 Dividend Compounding Machines Poised for 30%+ Total Returns by 2026

Cencora (COR) shares declined on Jun 27, following an unfavorable ruling from the Supreme Court related to a previously settled litigation. Here we discuss the key factors that likely led to the decline.

Cencora (COR) Stock Nosedives: Here's What Caused the Decline

Walgreens

Cencora stock and other drug distributors fell on Wednesday, hit by Walgreens results, not the ruling that killed an opioid settlement.

Drug Distributor Cencora Falls; Blame Walgreens, Not The Supreme Court

COR shares have advanced 13% since my last publication, adding conviction to the long-term thesis. The company has exceptional economic characteristics with abnormally high ROICs and negative working capital benefits. I have updated my price objectives to $270-$285 with a long-term intrinsic valuation of over $360 per share.

Cencora: Long-Term Compounder With Mouth-Watering Economics

Cencora (COR) gaining traction from the robust U.S. Healthcare Solutions segment raises optimism about the stock.

Cencora (COR) Gains 13.2% YTD: What's Driving the Stock?

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen Specialty Group (ABSG) is issuing a substitute notice to individuals who may have been impacted by a data security incident. ABSG's parent company previously announced the data security incident, which is fully contained. An investigation with the assistance of law enforcement, cybersecurity experts, and outside lawyers has now identified certain individuals whose personal information was involved in the incident. ABSG maintained this inform.

AmerisourceBergen Specialty Group Substitute Notice of Data Incident to Affected Individuals

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen Specialty Group, LLC (ABSG) is issuing notice to individuals who may have been impacted by a data security incident. ABSG's parent company previously announced the data security incident, which is fully contained. Through an investigation with the assistance of law enforcement, cybersecurity experts and outside lawyers, ABSG has now identified certain individuals whose personal information was involved in the incident. This information was m.

AmerisourceBergen Specialty Group Provides Substitute Notice of Data Incident to Affected Individuals

U.S. drug distributor Cencora has notified affected individuals that their personal and highly sensitive medical information was stolen during a cyberattack and data breach earlier this year, the company said on Friday.

Cencora notifies individuals about data stolen earlier this year

Cencora has agreed to buy about $400 million in stock back from Walgreens Boots Alliance, the second time the pharmacy chain has reduced its stake in the company this year as it looks to free up cash to pare down debt.

Cencora to buy $400 million in stock back from Walgreens

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $400 million in a private transaction. Cencora is also raising its fiscal year 2024 adjusted diluted earnings per share guidance to $13.35 to $13.55, up from the previous range of $13.30 to $13.50, to reflect a lower weighted average diluted share count, partially offset by higher net i.

Cencora Announces Common Share Repurchase From Walgreens Boots Alliance and Raises Fiscal 2024 Guidance

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has sold shares of Cencora, Inc. (NYSE: COR) pursuant to a share repurchase by Cencora in the amount of approximately $400 million. With the transaction, Walgreens Boots Alliance's ownership of Cencora's common stock has decreased from approximately 13 percent to approximately 12 percent. Proceeds to Walgreens Boots Alliance will be used primarily for debt paydown and general corporate purpose.

Walgreens Boots Alliance Sells Shares of Cencora for $400 Million of Proceeds

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global healthcare company, will convene leaders from across the healthcare and biopharmaceutical industries for its inaugural ThinkLive Cell and Gene Therapy (CGT) Summit, an event designed to explore the latest developments in the CGT sector and strategies to accelerate product commercialization and patient access. The two-day virtual event, which kicks off May 14, will feature panel discussions and presentations that cover key topics and consider.

Cencora To Host Inaugural ThinkLive Cell and Gene Therapy Summit

While the top- and bottom-line numbers for Cencora (COR) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Cencora (COR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Cencora, Inc. (NYSE:COR ) Q2 2024 Earnings Call Transcript May 1, 2024 8:30 AM ET Company Participants Bennett Murphy - SVP, Head of IR and Treasury Steve Collis - Chairman, President, and CEO Bob Mauch - EVP and COO Jim Cleary - EVP and CFO Conference Call Participants Elizabeth Anderson - Evercore Lisa Gill - JPMorgan Daniel Grosslight - Citi Eric Percher - Nephron Research Allen Lutz - Bank of America Stephanie Davis - Barclays Charles Rhyee - TD Cowen Michael Cherny - Leerink George Hill - Deutsche Bank Eric Coldwell - Baird Operator Hello and welcome to the Cencora Q2 2024 Earnings Call. My name is Alex and I'll be coordinating the call today.

Cencora, Inc. (COR) Q2 2024 Earnings Call Transcript

Cencora's (COR) second-quarter fiscal 2024 results benefit from overall market growth, including rising demand for GLP-1 drugs and COVID-19 vaccines. Inflationary pressure remains.

Cencora (COR) Q2 Earnings Top Estimates, 2024 View Raised

Cencora (COR) came out with quarterly earnings of $3.80 per share, beating the Zacks Consensus Estimate of $3.65 per share. This compares to earnings of $3.50 per share a year ago.

Cencora (COR) Q2 Earnings Top Estimates

News for Cencora Inc Stock (COR)